“Increasing Focus on Antibiotic Stewardship and Non-Antibiotic Therapies”
The global pharyngotonsillitis treatment market is witnessing a notable trend toward antibiotic stewardship and non-antibiotic therapies as awareness grows regarding antibiotic resistance. Pharyngotonsillitis, commonly caused by viral and bacterial infections, is often treated with antibiotics; however, overuse has raised significant concerns about antibiotic resistance, especially in recurrent cases. This has led to increased interest in alternative treatments, such as anti-inflammatory drugs, supportive care, and herbal therapies, which provide symptom relief without contributing to resistance issues. For instance, researchers are exploring the efficacy of corticosteroids in managing inflammation and pain in pharyngotonsillitis, reducing the need for antibiotics. Additionally, the market has seen an uptick in demand for products such as lozenges, analgesics, and antiseptic sprays, which offer symptomatic relief for viral pharyngotonsillitis cases. With healthcare professionals emphasizing reduced antibiotic use for viral cases, companies are innovating in non-antibiotic solutions, making this trend a key growth driver in the global pharyngotonsillitis treatment market.
